[1]
|
Chen, W., Zheng, R., Baade, P.D., et al. (2016) Cancer Statistics in China, 2015. CA: A Cancer Journal for Clinicians, 66, 115-132. https://doi.org/10.3322/caac.21338
|
[2]
|
Ning, S., Wei, W., Li, J., et al. (2018) Clinical Significance and Diagnostic Capacity of Serum TK1, CEA, CA 19-9 and CA 72-4 Levels in Gastric and Colorectal Cancer Patients. Journal of Cancer, 9, 494-501.
https://doi.org/10.7150/jca.21562
|
[3]
|
Wu, T., Merbl, Y., Huo, Y., et al. (2010) UBE2S Drives Elongation of K11-Linked Ubiquitin Chains by the Anaphase-Promoting Complex. Proceedings of the National Academy of Sciences of the United States of America, 107, 1355-1360. https://doi.org/10.1073/pnas.0912802107
|
[4]
|
Garnett, M.J., Mansfeld, J., Godwin, C., et al. (2009) UBE2S Elongates Ubiquitin Chains on APC/C Substrates to Promote Mitotic Exit. Nature Cell Biology, 11, 1363-1369. https://doi.org/10.1038/ncb1983
|
[5]
|
Paul, A. and Wang, B. (2017) RNF8- and Ube2S-Dependent Ubiquitin Lysine 11-Linkage Modification in Response to DNA Damage. Molecular Cell, 66, 458-472.e455. https://doi.org/10.1016/j.molcel.2017.04.013
|
[6]
|
Li, Z., Wang, Y., Li, Y., et al. (2018) Ube2s Stabilizes β-Catenin through K11-Linked Polyubiquitination to Promote Mesendoderm Specification and Colorectal Can-cer Development. Cell Death & Disease, 9, Article No. 456.
https://doi.org/10.1038/s41419-018-0451-y
|
[7]
|
Wang, L., Liang, Y., Li, P., et al. (2019) Oncogenic Activities of UBE2S Mediated by VHL/HIF-1α/STAT3 Signal via the Ubiquitin-Proteasome System in PDAC. OncoTargets and Therapy, 12, 9767-9781.
https://doi.org/10.2147/OTT.S228522
|
[8]
|
Liang, J., Nishi, H., Bian, M.L., et al. (2012) The Ubiqui-tin-Conjugating Enzyme E2-EPF Is Overexpressed in Cervical Cancer and Associates with Tumor Growth. Oncology Reports, 28, 1519-1525. https://doi.org/10.3892/or.2012.1949
|
[9]
|
Li, X., Elmira, E., Rohondia, S., et al. (2018) A Patent Review of the Ubiquitin Ligase System: 2015-2018. Expert Opinion on Therapeutic Patents, 28, 919-937. https://doi.org/10.1080/13543776.2018.1549229
|
[10]
|
Sheng, Y., Hong, J.H., Doherty, R., et al. (2012) A Human Ubiquitin Conjugating Enzyme (E2)-HECT E3 Ligase Structure-Function Screen. Molecular & Cellular Proteomics: MCP, 11, 329-341.
https://doi.org/10.1074/mcp.O111.013706
|
[11]
|
Chang, L., Zhang, Z., Yang, J., et al. (2015) Atomic Structure of the APC/C and Its Mechanism of Protein Ubiquitination. Nature, 522, 450-454. https://doi.org/10.1038/nature14471
|
[12]
|
Torre, L.A., Bray, F., Siegel, R.L., et al. (2015) Global Cancer Statistics, 2012. CA: A Cancer Journal for Clinicians, 65, 87-108. https://doi.org/10.3322/caac.21262
|
[13]
|
Gao, W. and Guo, C.B. (2009) Factors Related to Delay in Diagnosis of Oral Squamous Cell Carcinoma. Journal of Oral and Maxillofacial Surgery: Official Journal of the American Association of Oral and Maxillofacial Surgeons, 67, 1015-1020. https://doi.org/10.1016/j.joms.2008.12.022
|
[14]
|
Yoshimura, S., Kasamatsu, A., Nakashima, D., et al. (2017) UBE2S Associated with OSCC Proliferation by Promotion of P21 Degradation via the Ubiquitin-Proteasome System. Biochemical and Biophysical Research Communications, 485, 820-825. https://doi.org/10.1016/j.bbrc.2017.02.138
|
[15]
|
Cao, W., Chen, H.D., Yu, Y.W., et al. (2021) Changing Profiles of Cancer Burden Worldwide and in China: A Secondary Analysis of the Global Cancer Statistics 2020. Chinese Medical Journal (England), 134, 783-791.
https://doi.org/10.1097/CM9.0000000000001474
|
[16]
|
毛友生, 高树庚, 王群, 等. 中国食管癌临床流行特征及外科治疗概况大数据分析[J]. 中华肿瘤杂志, 2020, 42(3): 228-233.
|
[17]
|
Chen, M.F., Lee, K.D., Lu, M.S., et al. (2009) The Predictive Role of E2-EPF Ubiquitin Carrier Protein in Esophageal Squamous Cell Carcinoma. Journal of Molecular Medicine (Berlin), 87, 307-320.
https://doi.org/10.1007/s00109-008-0430-3
|
[18]
|
Ajani, J.A., Bentrem, D.J., Besh, S., et al. (2013) Gastric Cancer, Version 2.2013: Featured Updates to the NCCN Guidelines. Journal of the National Comprehensive Cancer Network: JNCCN, 11, 531-546.
|
[19]
|
Zhao, R., Yu, Z., Mao, X., et al. (2022) Knockout of UBE2S Inhibits the Proliferation of Gastric Cancer Cells and Induces Apoptosis by FAS-Mediated Death Receptor Pathway. Experimental Cell Research, 419, Article ID: 113293.
https://doi.org/10.1016/j.yexcr.2022.113293
|
[20]
|
Bray, F., Ferlay, J., Soerjomataram, I., et al. (2018) Global Can-cer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 68, 394-424.
https://doi.org/10.3322/caac.21492
|
[21]
|
Forner, A., Reig, M. and Bruix, J. (2018) Hepatocellular Carcinoma. The Lancet (London, England), 391, 1301-1314.
https://doi.org/10.1016/S0140-6736(18)30010-2
|
[22]
|
Tralhão, J.G., Dagher, I., Lino, T., et al. (2007) Treatment of Tumour Recurrence after Resection of Hepatocellular Carcinoma. Analysis of 97 Consecutive Patients. European Journal of Surgical Oncology: The Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 33, 746-751.
https://doi.org/10.1016/j.ejso.2006.11.015
|
[23]
|
Poon, R.T. (2011) Prevention of Recurrence after Resection of Hepatocellular Carcinoma: A Daunting Challenge. Hepatology (Baltimore, Md), 54, 757-759. https://doi.org/10.1002/hep.24569
|
[24]
|
Yen, Y., Lim, D.W., Chung, V., et al. (2008) Phase II Study of Oxaliplatin in Patients with Unresectable, Metastatic, or Recurrent Hepatocellular Cancer: A California Cancer Consortium Trial. American Journal of Clinical Oncology, 31, 317-322. https://doi.org/10.1097/COC.0b013e318162f57d
|
[25]
|
Ma, S., Lee, T.K., Zheng, B.J., et al. (2008) CD133+ HCC Cancer Stem Cells Confer Chemoresistance by Preferential Expres-sion of the Akt/PKB Survival Pathway. Oncogene, 27, 1749-1758. https://doi.org/10.1038/sj.onc.1210811
|
[26]
|
Gui, L., Zhang, S., Xu, Y., et al. (2021) UBE2S Promotes Cell Chemoresistance through PTEN-AKT Signaling in Hepatocellular Carcinoma. Cell Death Discovery, 7, Article No. 357. https://doi.org/10.1038/s41420-021-00750-3
|
[27]
|
Li, Q., Zhao, Y., Shi, X., et al. (2018) Ube2s Expression Is Ele-vated in Hepatocellular Carcinoma and Predicts Poor Prognosis of the Patients. International Journal of Clinical and Ex-perimental Pathology, 11, 781-787.
|
[28]
|
Pan, Y.H., Yang, M., Liu, L.P., et al. (2018) UBE2S Enhances the Ubiquitina-tion of p53 and Exerts Oncogenic Activities in Hepatocellular Carcinoma. Biochemical and Biophysical Research Com-munications, 503, 895-902.
https://doi.org/10.1016/j.bbrc.2018.06.093
|
[29]
|
Lim, J.H., Kim, D.G., Yu, D.Y., et al. (2019) Stabilization of E2-EPF UCP Protein Is Implicated in Hepatitis B Virus-Associated Hepatocellular Carcinoma Progression. Cellular and Molecular Life Sciences: CMLS, 76, 2647-2662.
https://doi.org/10.1007/s00018-019-03066-9
|
[30]
|
Hundal, R. and Shaffer, E.A. (2014) Gallbladder Cancer: Epide-miology and Outcome. Clinical Epidemiology, 6, 99-109. https://doi.org/10.2147/CLEP.S37357
|
[31]
|
Sharma, A., Sharma, K.L., Gupta, A., et al. (2017) Gallbladder Cancer Epidemiology, Pathogenesis and Molecular Genetics: Recent Update. World Journal of Gastroenterology, 23, 3978-3998.
https://doi.org/10.3748/wjg.v23.i22.3978
|
[32]
|
Roa, J.C., García, P., Kapoor, V.K., et al. (2022) Gallbladder Cancer. Nature Reviews Disease Primers, 8, Article No. 69. https://doi.org/10.1038/s41572-022-00398-y
|
[33]
|
曹进, 张景涛, 刘中砚, 等. 泛素结合酶E2s在胆囊癌患者中的高表达及意义[J]. 中华实验外科杂志, 2018, 35(7): 1321-1324.
|
[34]
|
Whittle, M.C., Izeradjene, K., Rani, P.G., et al. (2015) RUNX3 Controls a Metastatic Switch in Pan-creatic Ductal Adenocarcinoma. Cell, 161, 1345-1360. https://doi.org/10.1016/j.cell.2015.04.048
|